
Sign up to save your podcasts
Or


In the United States, about 80 percent of tests used to diagnose C. difficile are PCR assays. So what are the best options to diagnose and treat patients with this infection? To discuss the evolving treatment and evaluation landscape for C. difficile, Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor at Yale New Haven Hospital.
By ReachMD4.7
1818 ratings
In the United States, about 80 percent of tests used to diagnose C. difficile are PCR assays. So what are the best options to diagnose and treat patients with this infection? To discuss the evolving treatment and evaluation landscape for C. difficile, Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor at Yale New Haven Hospital.

137 Listeners

68 Listeners

1 Listeners

3 Listeners

3 Listeners

0 Listeners

6 Listeners

15 Listeners

0 Listeners

3,353 Listeners